Evidence with currently epidemic Sars-cov-2
There is some evidence demonstrating the efficacy of PT in COVID-19
patients. In a pilot study conducted in China on 10 severe COVID-19
patients, an improvement in clinical symptoms was recorded in all
patients within a few days of PT administration (15); in 7 patients,
transfusion of PT was associated with a decrease in viral load. Five
cases of COVID-19 severe patients were described , who reported a rapid
improvement in clinical status following transfusion, with convalescent
plasma (IgG titers SARS-CoV-2 >1000) (16). These two
studies also have a limited sample. In order to assess the effectiveness
of plasma convalescence therapy, another study conducted in patients
with severe COVID-19 showed that PT resulted in symptom alleviation,
changes in radiological abnormalities and laboratory tests and that no
obvious adverse effects were observed during treatment. (17) In
addition, a review was carried out to assess the effectiveness of PT in
patients with COVID-19. The results reported that PT in patients with
COVID-19 can reduce mortality in critical patients, the increase in
neutralizing antibody titers and the disappearance of SARS-CoV-2 RNA was
observed in almost all patients after therapy, a reduction in clinical
symptoms after administration of convalescent plasma. Based on the
results of this review, although data are limited, PT in the COVID-19
patient appears safe, clinically effective and reduces mortality. (18)